ANCA相关性血管炎首次复发2年风险预测模型的推导
基于PEXIVAS试验中649例达到缓解的AAV患者,100例在缓解后2年内首次复发。研究构建了包含性别、诱导治疗、ANCA亚型、临床表现和eGFR的风险预测模型,乐观校正后AUC为0.709,校准斜率为0.99。该模型有助于个体化监测与治疗决策,尚需外部验证。
要点
- 模型预测AAV缓解后2年内首次复发风险,AUC为0.709,校准良好。
- 预测因子包括性别、诱导治疗、ANCA亚型、呼吸/黏膜眼受累及缓解时eGFR。
- 模型尚需外部验证,暂不能直接用于临床决策。
核心结论
- 该模型可估算AAV患者达到疾病缓解后2年内首次复发的个体风险,可能有助于监测和治疗决策,但需未来外部验证。
研究设计与样本
- 对PEXIVAS试验中eGFR<50 mL/min/1.73 m2或弥漫性肺泡出血且达到缓解的AAV参与者进行事后分析。
- 纳入649例试验参与者,其中100例在缓解后2年内复发。
主要发现
- 最终风险预测模型包含性别、使用口服环磷酰胺或利妥昔单抗作为诱导药物、ANCA亚型、起病时非出血性呼吸受累或黏膜/眼受累、以及缓解时eGFR。
- 乐观校正后Harrell受试者工作特征曲线下面积为0.709(95%CI 0.707-0.710),校准斜率为0.99(95%CI 0.65-1.34)。
关键数值与推荐
- 模型预测对象为达到疾病缓解的AAV患者,预测结局为缓解后2年内首次复发。
- 模型最终纳入的预测因子:性别、口服环磷酰胺或利妥昔单抗诱导、ANCA亚型、非出血性呼吸或黏膜/眼受累、缓解时eGFR。
临床怎么用
- 该模型可用于估算AAV患者缓解后2年内首次复发风险,辅助制定监测与治疗策略,但需外部验证后方可常规使用。
局限性
- 本研究为PEXIVAS试验的事后分析,模型需未来外部验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: Individuals with antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV) differ in their risk of relapse. Estimation of an individual's risk may inform decision-making around monitoring and treatment. METHODS: We performed a post hoc analysis of participants with AAV with an estimated glomerular filtration rate (eGFR) <50 mL/min/1.73 m2 or diffuse alveolar haemorrhage enrolled in a trial assessing the effects of plasma exchange and a reduced glucocorticoid dosing regimen who achieved disease remission. We estimated the risk of first relapse within 2 years of remission. We first identified candidate predictors from the literature. Candidate predictors measured in our data set and associated with relapse within 2 years of remission underwent further selection using least absolute shrinkage and selection operator regression and time-to-event analysis. Model stability was assessed with variable inclusion, multiple shrinkage methods, and VanderWeele's E. Model discrimination was assessed using concordance statistics, and calibration using the slope. RESULTS: We included data from 649 trial participants, of whom 100 experienced a relapse within 2 years of remission. The final risk estimation model included sex, use of oral cyclophosphamide or rituximab as induction agent, ANCA subtype, nonhaemorrhagic respiratory involvement or mucous membrane/eye involvement at presentation, and eGFR at remission. The optimism-corrected Harrell's area under the receiver-operator curve 0.709 (95% CI 0.707-0.710). The calibration slope was 0.99 (95% CI 0.65-1.34). CONCLUSIONS: Our model estimates the risk of first relapse for individuals with AAV within 2 years after achieving disease remission. This may inform monitoring and treatment decisions. The model will benefit from future external validation.
引用
- Junek M, Ibrahim Q, Merkel PA, et al. Estimating 2-year risk of first relapse in ANCA-associated vasculitis: derivation of a risk-prediction model based on participants in the PEXIVAS trial. Ann Rheum Dis. 2026. PMID: 42772989. doi:10.1016/j.ard.2026.08.020
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。